DXRX Share Price | Diaceutics Plc Stock Analysis & Recommendation

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Compare Diaceutics Plc with Similar Stocks

Scancell Holdings Plc Oxford Biomedica Plc PureTech Health Plc

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

With a growth in Net Sales of 4.29%, the company declared Very Positive results in Dec 25

ROCE(HY) Highest at 0.24%
RAW MATERIAL COST(Y) Fallen by -14.88% (YoY)
NET SALES(Q) Highest at GBP 23.87 MM

With ROE of 0.24%, it has a very attractive valuation with a 3.06 Price to Book Value

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

GBP 124 Million (Small Cap)

P/E

124.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.17

Return on Equity

0.24%

Price to Book

3.06

Revenue and Profits:

Net Sales:

(Quarterly Results - )

Net Profit:

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

2.78%

6 Months

15.62%

1 Year

26.5%

2 Years

22.31%

3 Years

72.09%

4 Years

48.0%

5 Years

16.08%

Diaceutics Plc for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

24.79%

EBIT Growth (5y)

6.03%

EBIT to Interest (avg)

-1.06

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.32

Sales to Capital Employed (avg)

0.60

Tax Ratio

10.74%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

0.74%

ROE (avg)

0.95%

Valuation key factors

Factor

Value

P/E Ratio

124

Industry P/E

Price to Book Value

3.06

EV to EBIT

-116.91

EV to EBITDA

20.88

EV to Capital Employed

3.50

EV to Sales

3.04

PEG Ratio

1.17

Dividend Yield

ROCE (Latest)

-0.63%

ROE (Latest)

0.24%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Dow Theory

Mildly Bearish

OBV

No Trend

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by Diaceutics Plc"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 35.86% vs 21.54% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs -342.86% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "32.20",
          "val2": "23.70",
          "chgp": "35.86%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "2.30",
          "val2": "2.10",
          "chgp": "9.52%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.10",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.50",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.70",
          "val2": "-1.70",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-71.40%",
          "val2": "-114.70%",
          "chgp": "4.33%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

32.20

23.70

35.86%

Operating Profit (PBDIT) excl Other Income

2.30

2.10

9.52%

Interest

0.10

Exceptional Items

-0.50

0.00

Consolidate Net Profit

-1.70

Operating Profit Margin (Excl OI)

-71.40%

-114.70%

4.33%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 35.86% vs 21.54% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 0.00% vs -342.86% in Dec 2023

All Annual Results

Company CV

About Diaceutics Plc

Diaceutics Plc

Pharmaceuticals & Biotechnology

Diaceutics PLC is a United Kingdom-based data analytics and implementation services company which services the global pharmaceutical industry. The Company offers end to end services that encompasses from understanding the diagnostic landscape to test implementation into treatment pathways to enable better treatment decisions for patients. The Company’s data analytics and implementation services, including Landscape, Tracking, and Primary Market Research, leverages the diagnostic testing information to provide data-driven insights to drive seamless integration of diagnostic tests into treatment pathways. Its implementation services include Planning, Commercialization and Reimbursement Landscapes, to build the strategies and implement the tactics that drives optimal test utilization, ensuring that patients are getting the right treatment.

Company Coordinates

Company Details

727 Antrim Road , BELFAST NIR : BT2 8FE

Tel:

https://www.diaceutics.com/

Registrar Details